Zituvimet Xr Tablet, Film Coated, Extended Release
FDA Label NDC 70771-1880

1 label section · Submitted to the FDA by Zydus Lifesciences Limited · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Zydus Lifesciences Limited for the product Zituvimet Xr (NDC 70771-1880). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding package label.principal display panel, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Package Label.Principal Display Panel

NDC 70771-1879-6

ZITUVIMET® XR (sitagliptin and metformin hydrochloride extended-release) tablets

50 mg/500 mg

60 Tablets

Rx only

50 mg/500 mg (853cf721 7c0c 42ed 9243 Eb7cddd3574d 01)

50 mg/500 mg (853cf721 7c0c 42ed 9243 Eb7cddd3574d 01)

NDC 70771-1880-6

ZITUVIMET® XR (sitagliptin and metformin hydrochloride extended-release) tablets

50 mg/1,000 mg

60 Tablets

Rx only

50 mg-1000 mg (853cf721 7c0c 42ed 9243 Eb7cddd3574d 02)

50 mg-1000 mg (853cf721 7c0c 42ed 9243 Eb7cddd3574d 02)

NDC 70771-1881-3

ZITUVIMET® XR (sitagliptin and metformin hydrochloride extended-release) tablets

100 mg/1,000 mg

30 Tablets

Rx only

100 mg-1000 mg (853cf721 7c0c 42ed 9243 Eb7cddd3574d 03)

100 mg-1000 mg (853cf721 7c0c 42ed 9243 Eb7cddd3574d 03)

* Please review the disclaimer below.